Aragonda Apollo Hospitals introduces state-of-the-art Uro Laser Technology Unit
Apollo Hospitals in Aragonda has introduced a state-of-the-art ‘Uro Laser Technology Unit’ to improve the diagnosis and treatment of kidney stones and other nephrological conditions. The launch of this unit demonstrates the hospital’s dedication to providing high-quality healthcare services to rural communities. According to Dr. H.S. Shankar of Apollo Hospitals, the advanced laser technology employed in the unit enables minimally invasive and highly effective solutions for urological issues.
This cutting-edge technology allows for precise treatment with faster recovery times, significantly enhancing patient outcomes. The services offered by the Uro Laser Technology Unit will also be available under government-supported schemes, including Arogyasri and the Employees Health Scheme (EHS). This ensures that a broader segment of the population can access quality care, regardless of their financial means.
The introduction of this unit is a significant development for the region, as it provides patients with access to specialized urological care that was previously unavailable. The use of advanced laser technology is expected to reduce the need for invasive surgical procedures, resulting in less discomfort and scarring for patients. Furthermore, the faster recovery times enabled by this technology will allow patients to resume their normal activities more quickly, improving their overall quality of life.
The launch of the Uro Laser Technology Unit is part of Apollo Hospitals’ ongoing efforts to expand access to quality healthcare services in rural areas. By investing in advanced medical technology and expertise, the hospital aims to bridge the gap in healthcare services between urban and rural communities. The availability of these services under government-supported schemes is a significant step towards achieving this goal, as it ensures that quality healthcare is accessible to a wider segment of the population.
Overall, the introduction of the Uro Laser Technology Unit at Apollo Hospitals in Aragonda marks a significant milestone in the hospital’s mission to deliver world-class healthcare services to rural communities. With its advanced technology and commitment to accessibility, the unit is poised to make a positive impact on the lives of patients in the region.
Renowned institutions such as Kokilaben Hospital, Zydus Medtech, MSDE-Microsoft, IIT Mandi, and ART Fertility are key players.
India has witnessed significant advancements in various sectors, including public health, education, and sustainable mobility, in April 2025. Some of the key developments include:
* Kokilaben Dhirubhai Ambani Hospital being ranked among the world’s top medical institutions, recognizing its commitment to clinical excellence and patient care.
* Zydus Medtech partnering with Braile Biomedica to introduce state-of-the-art TAVI technology, improving access to advanced cardiac care in India.
* The Ministry of Skill Development and Entrepreneurship launching AI Careers for Women, a program aimed at increasing female participation in artificial intelligence and related fields.
* ART Fertility Clinics hosting an annual conference on reproductive medicine, focusing on patient-centric care, ethical practices, and the latest advances in assisted reproductive technologies.
* IIT Mandi leading a nationwide conclave to streamline academic governance, promoting collaboration, best practices, and technological innovation across all IITs.
In addition to these developments, several institutions have launched initiatives to drive innovation and growth. For example:
* GITAM University has established a Centre of Excellence for Robotics and Artificial Intelligence, aimed at driving research, innovation, and collaboration in emerging technologies.
* IIM Raipur and XLRI Jamshedpur have launched a leadership program inspired by nature’s principles, equipping business leaders with adaptive strategies and sustainable leadership skills.
* UPL Sustainable Agri Solutions has advanced public health through sustainable vector control initiatives, employing environmentally responsible solutions to eradicate mosquito-borne diseases.
* Wardwizard Innovations has reduced the prices of its electric two-wheelers, promoting electric mobility and sustainable transport solutions across India.
These developments demonstrate India’s capacity to drive meaningful advancements across various sectors, with a focus on innovation, sustainability, and social impact. They also reflect the country’s push towards future-ready education and innovation ecosystems, with a growing emphasis on technology, artificial intelligence, and clean energy.
Overall, April 2025 has been a significant month for India, marked by purpose-driven action and visionary growth across sectors. The country’s commitment to driving innovation, improving public health, and promoting sustainable development is evident in the various initiatives and collaborations launched during this period. As India continues to evolve and grow, it is likely that we will see even more exciting developments in the future, driven by the country’s vibrant startup ecosystem, innovative institutions, and forward-thinking leadership.
Biocon and Regeneron reach a settlement agreement, paving the way for the US launch of aflibercept biosimilar Yesafili.
Biocon Biologics, a biopharmaceutical company, has reached a settlement and license agreement with Regeneron to commercialize its aflibercept-jbvf (Yesafili) biosimilar, an interchangeable version of Regeneron’s aflibercept, in the United States. The agreement dismisses pending patent and litigation claims in the US District Court for the Northern District of West Virginia and the US Court of Appeals for the Federal Circuit. This move clears the path for Biocon Biologics to launch Yesafili in the US, with a potential launch date of the second half of 2026 or earlier if certain circumstances arise. The terms of the agreement are confidential.
Yesafili is intended for the treatment of various eye diseases, including neovascular age-related macular degeneration, retinal vein occlusion, diabetic macular edema, and myopic choroidal neovascularization. The US Food and Drug Administration (FDA) approved the biosimilar in May 2024, making Biocon Biologics the first to file an interchangeable biosimilar to Eylea, Regeneron’s market-leading treatment for these conditions. This agreement marks Biocon Biologics’ strategic entry into the ophthalmology market in the US, expanding its footprint and furthering its goal to increase access to life-changing treatments.
Biocon Biologics has already secured a settlement agreement in Canada with Bayer and Regeneron for the launch of Yesafili, with a planned launch date of no later than July 1, 2025. The company’s CEO and managing director, Shreehas Tambe, commented on the settlement, stating that it paves the way for Biocon Biologics to bring a reliable and high-quality aflibercept biosimilar to patients in the US. This agreement is a significant milestone for Biocon Biologics, as it represents the company’s first launch in the US ophthalmology market and a key step in its mission to increase access to life-changing treatments.
This settlement is a testament to Biocon Biologics’ scientific expertise and its ability to navigate complex patent and litigation disputes. The company is poised to become one of the first to market a biosimilar in the US, providing patients with a more affordable and accessible treatment option. As Biocon Biologics looks to expand its reach in the US market, this agreement is a significant step forward, demonstrating the company’s commitment to delivering innovative and life-changing treatments to patients.
Healthcare services of highest professional standards in Kolkata.
Healthcare Scan Diagnostics (HSD), a state-of-the-art diagnostic center in Kolkata, has partnered with Apollo Hospitals, Chennai to bring world-class healthcare expertise to patients in West Bengal. As part of this collaboration, renowned doctors from Apollo Hospitals, including specialists, will visit HSD on April 19-20 to consult patients in person. Following this initial visit, Apollo specialists will conduct regular OPD sessions at the clinic, making expert healthcare services more accessible to patients in the region.
This partnership aims to enhance patient care in Kolkata by leveraging Apollo’s renowned expertise and setting new standards in diagnostics and treatment. Dr. Haseeb Hassan, consultant senior neurologist and director of Healthcare Scan Diagnostics, expressed pride in the collaboration, stating that it will bring expert healthcare services to patients in the region, making world-class healthcare more accessible to everyone.
The partnership will also save patients time and trouble by minimizing the distance they would otherwise have to travel to Chennai for expert consultations. HSD’s goal is to offer comprehensive health solutions to the people of Kolkata and surrounding areas, providing the best services close at hand. The collaboration is expected to redefine the healthcare experience in the region and provide patients with access to top-notch medical care without having to travel long distances.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.